Evidence map›Paper›PMID 36031559›Full record

ArticleEuropean urology focus2022

PAM50 and Beyond: When Will Tissue Transcriptomics Guide Clinical Decision-making?

Samuel C Haywood, Shilpa Gupta, Hannelore V Heemers

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology focus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Samuel C HaywoodDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Shilpa GuptaDepartment of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Hannelore V HeemersDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: heemerh@ccf.org.
Cleveland Clinic · US

Funding

Towards selective androgen deprivation by targeting androgen activation of SRFR01CA166440 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HEEMERS, HANNELORE · 2014 to 2024
$3.4M
A novel determinant of prostate cancer growthR01CA248048 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI HEEMERS, HANNELORE · 2021 to 2025
$1.6M
NCI NIH HHS R01 CA166440NCI NIH HHS R01 CA248048
6 · The paper itself

Abstract

Emerging transcriptomics-based classifiers show promise as biomarkers to guide clinical decision-making in prostate cancer, but require further research, optimization, and validation.

Indexed as

Prostatic NeoplasmsTranscriptomeBiomarkers, TumorClinical Decision-MakingHumansMalePrognosisBiomarkers, Tumor

Identifiers

PMID36031559
PMCPMC9639163
OpenAlexW4293230403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.